


Healthcare News Roundup: Interventional Cardiology
HSMN NewsFeed - 11 Oct 2006
Volcano Announces First Permanent Installations of the Integrated s5i IVUS Imaging System
Volcano Announces First Permanent Installations of the Integrated s5i IVUS Imaging System
HSMN NewsFeed - 10 Oct 2006
Tryton Medical's Side-Branch Stent(TM) Treats Coronary Bifurcation Lesions With 100% Procedural Success
Tryton Medical's Side-Branch Stent(TM) Treats Coronary Bifurcation Lesions With 100% Procedural Success
HSMN NewsFeed - 5 Oct 2006
Conor Medsystems Receives Approval for One-Year Shelf Life for CoStar(R) Stent in the European Union
Conor Medsystems Receives Approval for One-Year Shelf Life for CoStar(R) Stent in the European Union
HSMN NewsFeed - 4 Oct 2006
Medtronic Announces Regulatory Approval for the Endeavor Drug-Eluting Coronary Stent System in Australia
Medtronic Announces Regulatory Approval for the Endeavor Drug-Eluting Coronary Stent System in Australia
HSMN NewsFeed - 4 Oct 2006
NMT Medical's BioSTAR(R) Data to be Presented at the 2006 TCT Scientific Symposium
NMT Medical's BioSTAR(R) Data to be Presented at the 2006 TCT Scientific Symposium
HSMN NewsFeed - 3 Oct 2006
Abbott Begins Early International Launch of XIENCE(TM) V Everolimus Eluting Coronary Stent System
Abbott Begins Early International Launch of XIENCE(TM) V Everolimus Eluting Coronary Stent System
HSMN NewsFeed - 21 Sep 2006
Cordis Corporation and Brivant Limited Sign Distribution Agreement for Three Interventional Products
Cordis Corporation and Brivant Limited Sign Distribution Agreement for Three Interventional Products
HSMN NewsFeed - 14 Sep 2006
MIV Therapeutics Names Harvard Interventional Cardiologist Dr. Joseph Carrozza to Scientific Advisory Board
MIV Therapeutics Names Harvard Interventional Cardiologist Dr. Joseph Carrozza to Scientific Advisory Board
HSMN NewsFeed - 7 Sep 2006
SurModics and X-Cell Medical Collaborate on Drug Eluting Stent Development
SurModics and X-Cell Medical Collaborate on Drug Eluting Stent Development
HSMN NewsFeed - 6 Sep 2006
TAXUS II Clinical Trial Follow-Up Data Demonstrates Excellent Long-Term Outcomes at Four Years
TAXUS II Clinical Trial Follow-Up Data Demonstrates Excellent Long-Term Outcomes at Four Years
